. 2022 Feb 19;30(5):1850–1868. doi: 10.1016/j.ymthe.2022.02.016

Table 3.

Unmodified mRNA COVID-19 vaccine candidates being tested in clinical trials

Name	Developer	Clinical phase, trial identifier	Dose, regimen	Antigen coding sequence	Formulation	Clinical outcome
CVnCoV	CureVac	phase IIb/III, NCT04652102 phase I, II, NCT04449276, NCT04515147	12 μg, p-b, 4 weeks	full-length S, 2P	Acuitas LNP	48% efficacy for the prevention of COVID-19 in age group 18–60 years¹²³
MRT5500 (VAW00001)	Translate Bio/Sanofi	phase I/II, NCT04798027	7.5 μg, p-b, 3 weeks	full-length S 2P, modified furin cleavage site	LNP	not published
ARCoV	AMS/Walvax/Suzhou	phase II, ChiCTR2100041855	15 μg, p-b, 2 to 4 weeks	RBD	LNP	not published
ARCoV	AMS/Walvax/Suzhou	phase III, NCT04847102	15 μg, p-b, 2 to 4 weeks	RBD	LNP	not published
PTX-COVID19B	Providence Therapeutics	phase I (II), NCT04765436	16, 40, 100 μg, p-b, 4 weeks; 40 μg was selected for phase II	full-length S	LNP	well tolerated in seronegative 18- to 64-year-old individuals, strong IgG antibody response¹²⁴
PTX-COVID19B	Providence Therapeutics	phase II, NCT05175742 comparison with BNT162b2	60, 80 μg, p-b, 4 weeks	full-length S	LNP	not published
DS5670	Daiichi Sankyo	phase I/II, NCT04821674	dose not disclosed, p-b	not disclosed	LNP	neutralizing activity without any safety concerns in both age groups (20–64 and 65–74 years)¹²⁵
SW-0123	Stemirna Therapeutics/Shanghai East Hospital	phase I, ChiCTR2100045984	10, 30, 60, 100 μg, p-b	full-length S	LPP	not published
EG-COVID	eyeGENE	phase I/IIa	50, 100, 200 μg, p-b, 3 weeks	full-length S	cationic liposome	not published

2P, two consecutive proline residues; AMS, Academy of Military Science of the Chinese People’s Liberation Army; IgG, immunoglobulin G; LNP, lipid nanoparticle; LPP, core-shell structured lipopolyplex; p-b, prime-boost regimen; RBD, receptor binding domain; S, spike protein.